35 years of experience building, operating, advising and funding entities across a broad spectrum of technologies and solutions, including digital content syndication, data exchange, vertical trading networks, e-commerce, interoperability, digital rights, artificial intelligence, configuration, fintech, workflow and medical devices.
AMA collaborator and advisor since 2015 focused on creating and launching the AMA’s innovation ecosystem in roles as Co-Founding Managing Partner of Health2047 Capital Partners Fund I; Board Member of Health2047 Inc; and Co-Founder and Co-Lead of the Integrated Healthcare Model Initiative (IHMI) for improving data relevance, portability and liquidity in healthcare. IHMI activities include conducting hundreds of interviews and field visits to identify problems and formulate solutions around the clinical, ethical, technical, economic, legal, regulatory and consensual challenges in healthcare data exchange.
Other relevant positions include CEO at Strategians, CEO at Edgenet (acquired by Syndigo), General Partner at Venrock Associates, Global Head of the Technology and Strategy Consulting at Arthur Andersen Business Consulting, Director on over a dozen public and private boards and various senior executive roles at companies in the data, software and system areas.
MBA from Stanford Graduate School of Business (Arjay Miller Scholar), MS and BS (Bronze Tablet and summa cum laude) from the University of Illinois – Champaign-Urbana, Executive Management Certificate in Strategy from Harvard Business School, and patents in the healthcare and product information spaces.
Joe Boystak, Co-Founder, Co-Chairman & President
Senior healthcare and life sciences investment banker having completed billions of dollars of financings, M&A and advisory transactions on a global scale across every segment of the healthcare industry; new company formation and venture capitalist with a focus on the convergence of healthcare and technology.
Founding Managing Partner, Health2047 Capital Partners Fund I; Founding Managing Director, Global Head Life Sciences Investment Banking, Jefferies; Strategic Advisor to the AMA in creating its innovation ecosystem and standing up Health2047, Inc; CEO, Brightwaters Capital.
Co-founder, Founding Director and Investor: Exosome Diagnostics (molecular Dx spinout from Harvard/MGH) sold to Bio-Techne [NASDAQ:TECH] for $250m plus $350m in milestone payments; GenoSpace (computational biology spinout team from Dana Farber) sold at a multiple of invested capital (undisclosed terms) to HCA Healthcare [NYSE:HCA]; Bruin Biometrics (wireless medical device spinout from UCLA) now commercial stage, recently named to TIME Magazine’s Best Inventions of 2020 list; PapiVax (immunotherapeutic spinout from Johns Hopkins) now in P2 clinical trials; PAIGE
(AI-enabled computational pathology spinout from Memorial Sloan Kettering) FDA 510(k) approval for its first-in-class AI-based platform product; Amicrobe (novel synthetic engineered proteins spinout from UCLA) initiating P1 clinical trials; among others. Named co-inventor for five US and EU first-in-class medical device patents. Served as a member of the Financial Innovation Lab at the Milken Institute/Faster Cures.
Currently, serves on the Johns Hopkins Bloomberg School of Public Health board, SoCalBio board; Chairman, Doctor Evidence, LLC; and Member of the “Trinity Challenge.”
Boston University, BA (cum laude); Johns Hopkins Bloomberg School of Public Health, MHS;
and Wharton School, Executive Education. Series 7 & 63 securities licenses.